Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanoma.

Saved in:
Bibliographic Details
Title: Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanoma.
Authors: Rawson, R.V.1,2,3,4 (AUTHOR), Maher, N.G.1,2 (AUTHOR), Menzies, A.M.1,2,5,6 (AUTHOR), Lo, S.N.1,2,7 (AUTHOR), Mesbah Ardakani, N.8 (AUTHOR), Jackett, L.A.9 (AUTHOR), Vergara, I.A.1,2,7 (AUTHOR), Pennington, T.E.1,2,3,6 (AUTHOR), Shannon, K.F.1,2,3,6 (AUTHOR), Ch'ng, S.1,2,3,6 (AUTHOR), Gonzalez, M.1 (AUTHOR), Burton, E.M.10 (AUTHOR), Lucas, M.W.11 (AUTHOR), Reijers, I.L.M.11 (AUTHOR), Rozeman, E.A.11 (AUTHOR), Gyorki, D.E.12 (AUTHOR), Sandhu, S.9 (AUTHOR), Carlino, M.S.1,2,13,14 (AUTHOR), Howle, J.13 (AUTHOR), Khattak, M.15 (AUTHOR)
Source: Annals of Oncology. Feb2026, Vol. 37 Issue 2, p206-216. 11p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2025.10.1237